Onward Therapeutics Discloses $28M Series B for Oncology
C. Grace Yeh brought Onward Therapeutics to Taiwan while keeping its European drug-development work in motion. The founder, Chairperson and CEO is now financing the next stretch of that arrangement: clinical programs, the supplies needed to run them and the discovery work behind the next candidates.
Onward disclosed a NT$900M Series B, approximately US$28M, on November 17, 2026. The financing had 2 closings, with the second completed in October. Returning and new investors are backing a Taipei-headquartered oncology business whose development relationships extend through Switzerland and France, giving the capital a cross-border operating assignment.
For a company pursuing treatments for resistant and relapsed cancers, continuity has a very practical meaning. A scientific program has to retain its people, institutional relationships and ability to manufacture investigational medicine as the corporate structure around it changes. Onward's financing puts more resources behind that continuing work.
Taiwan becomes the financing center for an existing development network
The Series B is Onward's first capital increase in Taiwan since its October 2025 share exchange. The company's restructuring announcement explained that the Taiwan entity became the global holding company, with the former Swiss parent becoming a wholly owned subsidiary. Existing shareholders maintained their ownership ratios and board composition, while licenses, intellectual property rights and ongoing R&D projects continued.
That arrangement gives the headquarters move more substance than a new address. Onward placed its corporate center closer to the biotechnology capital market it wants to access while preserving the organizations carrying its programs. The company described the restructuring as support for future fundraising and a potential public listing, connecting the financing decision to a longer corporate plan.
Existing shareholders CDIB Capital Healthcare Ventures and Hong Kong Chlitina International participated in the Series B. New institutions named in the announcement include Beiley Biofund, Everbright Biofund, Test Rite International, Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture and Top Taiwan Venture Capital. Individual investors also joined; the announcement did not identify a lead investor or disclose a valuation.
Onward reported approximately $90M in previous financing before the share exchange, originally denominated as CHF75.5M. That historical figure belongs to earlier rounds. The latest investment finances another stage of a company that has already assembled an international portfolio and the relationships needed to advance it.
The founders have built around several routes into oncology
Grace Yeh's background includes founding and leading PharmaEngine before Onward. She founded Onward in November 2019 with Alain Herrera, its CMO, and Armand de Gramont. Herrera brought oncology and hematology training alongside experience leading oncology businesses, giving the founding team a history that spans scientific development and the organizations built around it.
The current management page lists de Gramont as President of R&D and Patrick Nielly as COO. Onward's financing announcement dates de Gramont's promotion to April 2026. Responsibility for the next development decisions therefore sits with a founding team whose roles have evolved along with the portfolio.
Onward's model combines licensed candidates, investments in partners and internal research. Its collaboration structure includes a worldwide license and co-development relationship with Biomunex around OT-A201, and majority ownership of Emercell, which develops the OT-C001 cell-therapy program. Those are different ways of bringing external scientific work into a company capable of carrying development forward.
The commercial significance lies in the handoff. A license supplies rights to pursue a program; the recipient still takes on the work of developing it. Equity relationships add another connection between scientific capability and the organization financing its progress, making partner continuity part of the operating model.
Clinical programs give the new capital a specific job
Onward's pipeline spans antibodies, cell therapy and small molecules, with development stages varying across the portfolio. In its latest announcement, the company said OT-A201, a tetravalent bispecific antibody, had advanced to Phase 1b in solid tumors after completing monotherapy dose escalation. Its hematologic-malignancy study remained in Phase 1a, with enrollment completion targeted for the end of 2026.
OT-C001 uses donor-derived natural killer cells from umbilical cord blood. The company says it is being studied with rituximab in a French Phase 1 trial for people with diffuse large B-cell lymphoma after relapse or resistance following prior CAR-T and T-cell engager therapies. Enrollment and follow-up continue, making the development work an ongoing clinical investigation.
Manufacturing clinical supplies belongs inside that investigation. Onward explicitly includes it among the uses of the Series B, alongside clinical programs and early-stage R&D. The allocation makes visible a practical relationship between scientific ambition and the physical material required to continue studying a candidate.
Earlier research is also progressing through institutional partnerships. Onward's October 2025 licensing announcement connected its OT-S00X metabolism program to work with Institut du Cancer de Montpellier, Inserm and Université de Montpellier that began under a 2021 collaboration. Funding discovery alongside clinical programs maintains a route for additional candidates to enter the portfolio as the existing ones develop.
A larger Taiwan team will join the clinical work
Onward plans to expand its Taiwan team and begin clinical trials there. The company has also signed a listing advisory agreement and is preparing for a targeted registration on the Taipei Exchange's Emerging Stock Board by the end of 2027. Both activities remain forward-looking plans, with the clinical and corporate work proceeding on their own schedules.
For operators following biotechnology financing, Onward provides a specific example of capital geography meeting scientific continuity. Taiwan is becoming a larger center of funding and organizational responsibility, while European subsidiaries and partners remain part of the development effort. The Series B supports the people and supplies that keep those relationships productive as the programs move through trials and the Taiwan team takes on more of the work.
Biotech funding, last 30 days
DevCuration's funding database tracked 17 Biotech rounds totaling $4.4B in disclosed capital over the past 30 days. Recent deals we covered:
- Johnson & Johnson Agrees to $2.2B Ollin Biosciences BuyoutM&A · $2.2B upfront · Nov 17
- Seawolf Therapeutics Raises $100M in Seed and Series ASeed and Series A · $100M · Nov 17
- Sofinnova Partners Closes $815M Crossover II FundFund Final Close · $815M · Nov 16
- Neurosterix Raises $105M for Schizophrenia Phase 2 PlansSeries B · $105M · Nov 14
- Araceli Biosciences Raises $4.5M for Cell Imaging Growth$4.5M · Nov 13
Frequently Asked Questions
Why does Onward’s move to Taiwan matter for the Series B?
The round is its first capital increase in Taiwan after an October 2025 share exchange made the Taiwan entity the global holding company. Swiss and French operations continued, connecting Taiwan fundraising to an existing European development network.
How do OT-A201 and OT-C001 differ?
OT-A201 is a bispecific antibody program licensed from Biomunex. OT-C001 is a donor-derived NK-cell therapy from majority-owned Emercell, being studied with rituximab in a French Phase 1 lymphoma trial.
Why are clinical supplies part of the financing plan?
Investigational medicines have to be manufactured for clinical programs to continue. Onward names clinical-supply manufacturing alongside clinical development and early-stage R&D as uses of the Series B.
Was the Series B completed when it was announced in November?
The November 17 English-language announcement disclosed a round raised through 2 closings. The company says the second closing took place in October 2026.
What does the planned Emerging Stock Board registration represent?
Onward says it has signed a listing advisory agreement and is preparing for registration by the end of 2027. It remains a company target rather than a completed listing.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved